AU2015301097B2 - Drug combinations to treat multiple myeloma - Google Patents

Drug combinations to treat multiple myeloma Download PDF

Info

Publication number
AU2015301097B2
AU2015301097B2 AU2015301097A AU2015301097A AU2015301097B2 AU 2015301097 B2 AU2015301097 B2 AU 2015301097B2 AU 2015301097 A AU2015301097 A AU 2015301097A AU 2015301097 A AU2015301097 A AU 2015301097A AU 2015301097 B2 AU2015301097 B2 AU 2015301097B2
Authority
AU
Australia
Prior art keywords
cancer
compound
administered
subject
proteasome inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015301097A
Other languages
English (en)
Other versions
AU2015301097A1 (en
Inventor
Dana T. Aftab
Peter Lamb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of AU2015301097A1 publication Critical patent/AU2015301097A1/en
Application granted granted Critical
Publication of AU2015301097B2 publication Critical patent/AU2015301097B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2015301097A 2014-08-05 2015-08-05 Drug combinations to treat multiple myeloma Active AU2015301097B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462033386P 2014-08-05 2014-08-05
US62/033,386 2014-08-05
PCT/US2015/043825 WO2016022697A1 (en) 2014-08-05 2015-08-05 Drug combinations to treat multiple myeloma

Publications (2)

Publication Number Publication Date
AU2015301097A1 AU2015301097A1 (en) 2017-03-02
AU2015301097B2 true AU2015301097B2 (en) 2021-03-04

Family

ID=53836256

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015301097A Active AU2015301097B2 (en) 2014-08-05 2015-08-05 Drug combinations to treat multiple myeloma

Country Status (13)

Country Link
US (1) US11065240B2 (enExample)
EP (1) EP3177311B1 (enExample)
JP (2) JP6892381B2 (enExample)
KR (1) KR102634247B1 (enExample)
CN (1) CN106573042A (enExample)
AU (1) AU2015301097B2 (enExample)
BR (1) BR112017002318A2 (enExample)
CA (1) CA2957466C (enExample)
EA (1) EA034992B1 (enExample)
MA (1) MA40457A (enExample)
MX (1) MX382904B (enExample)
UA (1) UA121482C2 (enExample)
WO (1) WO2016022697A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EP3738952A1 (en) 2014-02-14 2020-11-18 Exelixis, Inc. Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
JP6666849B2 (ja) 2014-03-17 2020-03-18 エグゼリクシス， インコーポレイテッド カボザンチニブ製剤の投与
EP3174854B1 (en) 2014-07-31 2022-08-24 Exelixis, Inc. Method of preparing fluorine-18 labeled cabozantinib and its analogs
CN106573042A (zh) 2014-08-05 2017-04-19 埃克塞里艾克西斯公司 治疗多发性骨髓瘤的药物组合
CN109069499A (zh) 2016-04-15 2018-12-21 埃克塞里艾克西斯公司 使用 n-(4-(6,7-二甲氧基喹啉-4-基氧基)苯基)-n’-(4-氟苯基)环丙烷-1,1-二甲酰胺,(2s)-羟基丁二酸盐治疗肾细胞癌的方法
WO2019053611A1 (en) * 2017-09-14 2019-03-21 Glaxosmithkline Intellectual Property Development Limited POLY THERAPY FOR THE TREATMENT OF CANCER
MA51673B1 (fr) 2018-01-26 2025-10-31 Exelixis, Inc. Composés pour le traitement des troubles dépendants de kinases
EP3806858A4 (en) 2018-06-15 2022-03-09 Handa Pharmaceuticals, Inc. KINA INHIBITOR SALTS AND COMPOSITIONS THEREOF
WO2023222946A1 (en) 2022-05-18 2023-11-23 Fermion Oy Process for the preparation of cabozantinib
EP4658271A1 (en) 2023-01-31 2025-12-10 Handa Oncology, LLC Improved cabozantinib compositions and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7579473B2 (en) * 2003-09-26 2009-08-25 Exelixis, Inc. c-Met modulators and methods of use

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6402215B1 (en) * 1996-05-21 2002-06-11 American Moto Products, Inc. Vehicle cargo bed extender
EP1773826A4 (en) 2004-07-02 2009-06-03 Exelixis Inc MODULATORS OF C-MET AND THEIR METHOD OF USE
CA2603748A1 (en) 2005-04-06 2006-10-12 Exelixis, Inc. C-met modulators and methods of use
JP5311673B2 (ja) 2006-12-14 2013-10-09 エグゼリクシス， インコーポレイテッド Ｍｅｋ阻害剤の使用方法
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
UY32142A (es) 2008-09-26 2010-05-31 Smithkline Beckman Corp Preparación de una quinoliniloxidifenilciclopropanodicarboxamida
WO2010056960A1 (en) 2008-11-13 2010-05-20 Exelixis Inc. Methods of preparing quinoline derivatives
CN102239148A (zh) 2008-12-04 2011-11-09 埃克塞里艾克西斯公司 喹啉衍生物的制备方法
DK2387563T4 (da) 2009-01-16 2022-07-18 Exelixis Inc Malatsalt af n-(4-{ [ 6, 7-bis(methyloxy)quinolin-4-yl]oxy}phenyl-n'-(4-fluorphenyl)cyclopropan-1,1-dicarboxamid, og krystallinske former deraf til behandling af cancer
JP2012533570A (ja) 2009-07-17 2012-12-27 エグゼリクシス， インコーポレイテッド Ｎ−［３−フルオロ−４−（｛６−（メチルオキシ）−７−［（３−モルホリン−４−イルプロピル）オキシ］−キノリン−４−イル｝オキシ）フェニル］−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボキサミドの結晶形
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EA025304B1 (ru) * 2010-02-03 2016-12-30 Инсайт Холдингс Корпорейшн ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИНЫ В КАЧЕСТВЕ c-Met ИНГИБИТОРОВ
MX2012010506A (es) 2010-03-12 2012-10-15 Exelixis Inc Formas cristalinas hidratadas del n-[3-fluoro-4-({6-(metiloxi)-7-[ (3-morfolin-4-ilpropil)oxi]-quinolin-4-il}oxi)fenil]-n'-(4-fluoro fenil)ciclopropano-1,1-dicarboxamida.
US20120070368A1 (en) 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
SG187060A1 (en) 2010-07-16 2013-02-28 Exelixis Inc C-met modulator pharmaceutical compositions
EP2593091A1 (en) 2010-07-16 2013-05-22 Exelixis, Inc. C-met modulator pharmaceutical compositions
AU2011307306A1 (en) 2010-09-27 2013-05-02 Exelixis, Inc. Dual inhibitors of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
US20140057943A1 (en) 2010-09-27 2014-02-27 Exelixix, Inc. Method of Treating Cancer
CN103391773A (zh) 2010-09-27 2013-11-13 埃克塞里艾克西斯公司 用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂
WO2012064967A2 (en) * 2010-11-10 2012-05-18 Cedars-Sinai Medical Center Cancer cell-derived receptor activator of the nf-kb ligand drives bone and soft tissue metastases
US20130252956A1 (en) 2010-11-22 2013-09-26 Howard Kallender Methods of treating cancer
KR20230158644A (ko) 2011-02-10 2023-11-20 엑셀리시스, 인코포레이티드 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
WO2012151326A1 (en) 2011-05-02 2012-11-08 Exelixis, Inc. Method of treating cancer and bone cancer pain
TW201306842A (zh) 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
CA2848512A1 (en) 2011-09-22 2013-03-28 Exelixis, Inc. Method for treating osteoporosis
BR112014009302B1 (pt) 2011-10-20 2020-04-28 Exelis Inc Us/Us processo para preparar derivados de quinolina
EA201490944A1 (ru) 2011-11-08 2014-10-30 Экселиксис, Инк. Двойной ингибитор met и vegf для лечения рака
CA2863986A1 (en) * 2012-02-06 2013-08-15 The Regents Of The University Of California Emp2 regulates angiogenesis in cancer cells through induction of vegf
CN103304552B (zh) * 2012-03-09 2016-12-28 广东东阳光药业有限公司 取代的吡啶化合物及其使用方法和用途
US9861624B2 (en) 2012-05-02 2018-01-09 Exelixis, Inc. Method of treating cancer
US20140121239A1 (en) 2012-09-07 2014-05-01 Exelixis, Inc. Method of treating lung adenocarcinoma
US20140221372A1 (en) 2013-02-06 2014-08-07 GlaxoSmithKline Intellectual Property (NO 2.) Limited Method of administration and treatment
GEP20196995B (en) 2013-03-15 2019-07-25 Inc Exelixis Metabolites of n-(4-{[6,7-bis (methyloxy)quinolin-4-yl] oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
AU2014248001A1 (en) 2013-04-04 2015-11-19 Exelixis, Inc. Drug combinations to treat cancer
ES2927651T3 (es) 2013-04-04 2022-11-10 Exelixis Inc Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer
EP3738952A1 (en) 2014-02-14 2020-11-18 Exelixis, Inc. Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
JP6666849B2 (ja) 2014-03-17 2020-03-18 エグゼリクシス， インコーポレイテッド カボザンチニブ製剤の投与
BR112016024672A2 (pt) 2014-04-25 2021-02-02 Exelixis, Inc método para o tratamento de adenocarcinoma de pulmão
EP3174854B1 (en) 2014-07-31 2022-08-24 Exelixis, Inc. Method of preparing fluorine-18 labeled cabozantinib and its analogs
CN106573042A (zh) 2014-08-05 2017-04-19 埃克塞里艾克西斯公司 治疗多发性骨髓瘤的药物组合
WO2016061253A1 (en) 2014-10-14 2016-04-21 Exelixis, Inc. Drug combination to treat melanoma

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7579473B2 (en) * 2003-09-26 2009-08-25 Exelixis, Inc. c-Met modulators and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Mari I Suominen: "Effects of Cabozantinib in the 5TGM1 murine multiple myeloma model ", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 106, 5 April 2014 (2014-04-05), XP055626787 GB, ISSN: 0027-8874, DOI: 10.1093/lnci/dju033 *

Also Published As

Publication number Publication date
AU2015301097A1 (en) 2017-03-02
MX2017001490A (es) 2017-05-11
EP3177311B1 (en) 2024-10-30
EP3177311C0 (en) 2024-10-30
UA121482C2 (uk) 2020-06-10
EA201790312A1 (ru) 2017-06-30
EP3177311A1 (en) 2017-06-14
JP6892381B2 (ja) 2021-06-23
KR20170031786A (ko) 2017-03-21
BR112017002318A2 (pt) 2018-07-17
JP2017526662A (ja) 2017-09-14
JP2020002179A (ja) 2020-01-09
EA034992B1 (ru) 2020-04-15
KR102634247B1 (ko) 2024-02-05
MA40457A (fr) 2017-06-14
CA2957466A1 (en) 2016-02-11
CN106573042A (zh) 2017-04-19
US20170224672A1 (en) 2017-08-10
WO2016022697A1 (en) 2016-02-11
CA2957466C (en) 2023-10-17
MX382904B (es) 2025-03-13
US11065240B2 (en) 2021-07-20

Similar Documents

Publication Publication Date Title
AU2015301097B2 (en) Drug combinations to treat multiple myeloma
TWI730013B (zh) 用於治療癌症的四環喹諾酮類似物組合療法
RU2730506C2 (ru) Твердые формы соединения, модулирующего киназы
US20160287605A1 (en) Combination therapy
US9682082B2 (en) Combinations of AKT and MEK inhibitor compounds, and methods of use
WO2025067459A2 (en) Therapies for the treatment of cancer
JP2024546605A (ja) がんを治療するための併用療法の使用
JP2024538117A (ja) Ｗｅｅ１阻害剤と抗ｃｄ４７抗体との組み合わせ。
EP3852744A1 (en) Combination therapy for the treatment of uveal melanoma
EP3525794A1 (en) Apilimod compositions and methods for using same in the treatment of alzheimer's disease
WO2023031798A1 (en) Dosing regimen for a tead inhibitor
CN118201616A (zh) 用于癌症的wee1抑制剂
US20240360135A1 (en) Imidazo[1,2-b]pyridazinyl compounds and uses thereof
US20240091226A1 (en) Forms and Formulations Of A Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitor
RU2786570C2 (ru) Комбинированная терапия тетрациклическими аналогами хинолона для лечения рака
WO2024246824A1 (en) Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer
CA3198190A1 (en) Use of sodium trans-[tetrachloridobis(1h-indazole)ruthenate(iii)] for treating cancers
NZ617243B2 (en) Combinations of akt and mek inhibitor compounds, and methods of use

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)